![]() | Only 14 pages are availabe for public view |
Abstract In the 21st century, cancer is still a problem. It is a genetic disease that progresses via development of multistep carcinogenesis with the participation of various physiological systems in the human body, such as cell signaling and apoptosis, and as a result, cancer is extremely complicated to combat. Generally, cancer begins as a local disease, but it metastasizes over time, making it difficult to cure. It is the leading cause of death in developed countries Ehrlich ascites carcinoma (EAC) is a transplantable, poorly differentiated malignant tumor and one of the experimental breast tumor derived from spontaneous mouse adeno-carcinoma. Similar to other tumors developing in body cavities, EAC cells fill the peritoneal cavity by rapid division of cells, accumulation of a fluid named ascitic fluid and animal dies 17-18 days following EAC transplantation. The interesting anticancer properties of imidazoles inspired the prevalent development of their derivatives with the hope of increasing the efficiency and lowering the side effects. The experimental evidence indicated that the different types of cancers originate because of a change in the structure and function of DNA (deoxyribonucleic acid), VEGF (vascular endothelial growth factor), topoisomerase I & II, mitotic spindle microtubules, histone deacetylases, receptor tyrosine kinases, topoisomerases, CYP26A1 enzyme, etc. Imidazole has the potential to overcome the unresolved disadvantages of currently available clinical drugs and could be utilized as a chemical scaffold for novel anticancer agents with several potential mechanisms of action. Therefore, it has been involved in various studies |